Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

Sponsor
National Taiwan University Hospital
Study ID
NCT00681603
Status
Completed

Conditions

  • Herpetic Keratopathy
  • Lipid Keratopathy
  • Penetrating Keratoplasty
  • Rosacea

Eligibility Criteria

Sex
All
Age
10 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg) — DRUG
    subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.

Study Details

1. Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization. 2. Material and methods: We enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response. 3. Main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.

Key Dates

First listed
May 21, 2008
Start date
Aug 31, 2007
Status verified
Aug 2007
Primary completion
Feb 29, 2008
Completion
Feb 29, 2008

Study Design

Enrollment
13 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    13 cases that accepted subconjunctival injection of bevacizumab

Primary Outcome Measure

Resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity [ Time Frame: prospective ]

Related Studies